铃蟾肽受体激活蛋白通过调控SIRT2降解加重顺铂诱导的急性肾损伤
本研究利用Bc004004敲除小鼠和HK2细胞,探讨铃蟾肽受体激活蛋白(BRAP)在顺铂诱导的急性肾损伤(AKI)中的作用及机制。BRAP在AKI小鼠和人类肾脏中下调,其缺失减轻肾小管细胞凋亡和坏死性凋亡,而局部过表达则加重损伤。机制上,P65抑制BRAP转录,BRAP通过影响SIRT2与E3泛素连接酶HRD1的相互作用及后续蛋白酶体降解来调控SIRT2蛋白水平。
要点
- BRAP在顺铂诱导的AKI小鼠和人类肾脏中表达下调。
- Bc004004缺失减轻肾小管细胞凋亡和坏死性凋亡,而BRAP过表达加重损伤。
- BRAP通过影响SIRT2与HRD1的相互作用及蛋白酶体降解调控SIRT2蛋白水平。
核心结论
- BRAP在顺铂诱导的AKI中通过调控SIRT2降解参与肾小管细胞凋亡和坏死性凋亡,安全有效的BRAP抑制剂可能成为AKI的治疗选择。
研究设计与样本
- 使用Bc004004敲除小鼠和HK2细胞,结合ChIP-Seq和RNA-Seq数据分析,在体外和体内研究BRAP对AKI的影响。
主要发现
- BRAP在顺铂诱导的AKI小鼠和人类肾脏中下调,全局Bc004004缺失减轻肾小管细胞凋亡和坏死性凋亡,而肾脏局部过表达BRAP加重上述损伤。
- 泛半胱天冬酶抑制剂Z-VAD预处理减轻野生型小鼠顺铂诱导的血肌酐升高和肾损伤,但在BRAP-/-小鼠中无此作用。
- Z-VAD在顺铂处理的HK2细胞中的细胞保护作用强于坏死性凋亡抑制剂necrostatin-1(Nec-1),Nec-1预处理减少BRAP过表达HK2细胞的顺铂诱导细胞死亡,但对BRAP水平正常的细胞无效。
- 顺铂处理激活核因子-κB亚基P65,抑制P65增加HK2细胞中BRAP的mRNA水平,ChIP和双荧光素酶报告基因实验证实P65结合C6ORF89启动子并在顺铂处理时降低其mRNA表达。
- SIRT2在顺铂诱导的AKI中下调,BRAP水平直接影响SIRT2蛋白水平,BRAP通过影响SIRT2与E3泛素连接酶HRD1的相互作用及后续蛋白酶体降解来调控SIRT2蛋白水平。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute kidney injury (AKI) is a public health problem with no specific therapies in the clinic and the underlying pathogenesis of AKI remains obscure. Bombesin receptor-activated protein (BRAP, C6ORF89 protein) was initially discovered as a ligand for a previously orphan G-protein-coupled receptor bombesin-like receptor-3. At present, accepted biological effects of BRAP include cell cycle progression, wound repair and the activation of histone deacetylases. However, its role in kidney disease is unknown. In this study we have investigated the role of BRAP and underlying mechanisms involved in cisplatin (CP)-induced AKI. METHODS: Here we used Bc004004 (homologous of C6ORF89 in mice) knockout mice and HK2 cells to investigate the effect of BRAP on AKI in vitro and in vivo. We analyzed ChIP-Seq and RNA-Seq data to search for the upstream regulators of BRAP and downstream mediators of BRAP action in AKI. Immunostaining, real-time polymerase chain reaction (PCR), co-immunoprecipitation, a dual-luciferase reporter assay and ChIP-PCR assay were applied to reveal the upstream and downstream regulation mechanism of BRAP during cisplatin-induced AKI. RESULTS: BRAP was downregulated in mice and human kidneys with AKI. Global Bc004004 deletion alleviated tubular cell apoptosis and necroptosis in CP-induced AKI mice, whereas local overexpression of BRAP in kidneys aggravated them. Pan-caspase inhibitor Z-VAD pretreatment attenuated CP-induced blood creatinine increase and kidney injury in wild-type mice but not in BRAP -/- mice. The activation of mixed lineage kinase like-domain was magnified by Z-VAD in CP-treated mice, especially in BRAP -/- mice. The cytoprotective effect of Z-VAD was more substantial than necrostatin-1 (Nec-1, an inhibitor of necroptosis) in CP-treated human kidney proximal tubular epithelial (HK2) cells. Furthermore, Nec-1 pretreatment reduced the CP-induced cell death in BRAP overexpression HK2 cells but did not work in cells with normal BRAP levels. We determined that CP treatment activated the nuclear factor-κB subunit P65 and inhibition of P65 increased the messenger RNA (mRNA) levels of BRAP in HK2 cells. The chromatin immunoprecipitation assay and dual-luciferase reporter gene assay verified P65 binding to the C6ORF89 promoter and reduced its mRNA expression upon CP treatment. Next we found that sirtuin 2 (SIRT2) was downregulated in CP-induced AKI and BRAP levels directly impacted the protein levels of SIRT2. Our findings further confirmed that BRAP regulates the SIRT2 protein levels by affecting SIRT2's interactions with E3 ubiquitin ligase HRD1 and subsequent proteasomal degradation. CONCLUSIONS: Our results demonstrated that BRAP played an important role in tubular cell apoptosis and necroptosis during CP-induced AKI. Safe and efficient BRAP inhibitors might be effective therapeutic options for AKI.
引用
- Peng L, Liu D, Liu H, et al. Bombesin receptor-activated protein exacerbates cisplatin-induced AKI by regulating the degradation of SIRT2. Nephrol Dial Transplant. 2022. PMID: 35488871. doi:10.1093/ndt/gfac164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。